Medigen Biotechnology Corp. (TPEX:3176)

Market Cap	4.21B
Revenue (ttm)	1.62B
Net Income (ttm)	-26.50M
Shares Out	139.31M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,722
Average Volume	77,357
Open	30.15
Previous Close	30.25
Day's Range	30.10 - 30.75
52-Week Range	23.65 - 43.90
Beta	0.32
RSI	53.78
Earnings Date	Aug 14, 2025

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 3176

Financial Performance

In 2024, Medigen Biotechnology's revenue was 1.37 billion, an increase of 18.57% compared to the previous year's 1.16 billion. Losses were -204.69 million, -63.53% less than in 2023.